Primary Hyperoxaluria Type I

Also known as: Primary Hyperoxaluria Type 1 / Primary Hyperoxaluria Type 1 (PH1) / Primary hyperoxaluria, type I (disorder)

Drug	Drug Name	Drug Description
DB15935	Lumasiran	Lumasiran is an interfering RNA that silences hydroxyacid oxidase 1 for the treatment of primary hypoxaluria type 1.
DB17635	Nedosiran	An antisense oligonucleotide used to treat primary hyperoxaluria type 1 in adults and high oxalate levels in children

Drug	Drug Name	Target	Type
DB15935	Lumasiran	Hydroxyacid oxidase 1	target
DB15935	Lumasiran	Serum albumin	carrier
DB15935	Lumasiran	Cytochrome P450 2C8	enzyme
DB17635	Nedosiran	L-lactate dehydrogenase A chain	target

Drug	Drug Name	Phase	Status	Count
DB17663	DCR-PH1	1	Terminated	1
DB15935	Lumasiran	1 / 2	Completed	1
DB17635	Nedosiran	2	Completed	1
DB17635	Nedosiran	2	Recruiting	2
DB15935	Lumasiran	3	Active Not Recruiting	2
DB15935	Lumasiran	3	Completed	1
DB17635	Nedosiran	3	Enrolling by Invitation	1
DB17635	Nedosiran	Not Available	Available	1